DE69804446T3 - Verfahren um quantitativen informationen über einflüsse auf zelluläre reaktionen zu entnehmen - Google Patents
Verfahren um quantitativen informationen über einflüsse auf zelluläre reaktionen zu entnehmen Download PDFInfo
- Publication number
- DE69804446T3 DE69804446T3 DE69804446T DE69804446T DE69804446T3 DE 69804446 T3 DE69804446 T3 DE 69804446T3 DE 69804446 T DE69804446 T DE 69804446T DE 69804446 T DE69804446 T DE 69804446T DE 69804446 T3 DE69804446 T3 DE 69804446T3
- Authority
- DE
- Germany
- Prior art keywords
- gfp
- seq
- cells
- fusion
- influence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000000034 method Methods 0.000 title claims abstract description 111
- 238000006243 chemical reaction Methods 0.000 title description 12
- 102000001253 Protein Kinase Human genes 0.000 claims abstract description 30
- 108060006633 protein kinase Proteins 0.000 claims abstract description 30
- 230000001419 dependent effect Effects 0.000 claims abstract description 16
- 102000008130 Cyclic AMP-Dependent Protein Kinases Human genes 0.000 claims abstract description 13
- 108010049894 Cyclic AMP-Dependent Protein Kinases Proteins 0.000 claims abstract description 12
- 230000031146 intracellular signal transduction Effects 0.000 claims abstract description 12
- 102000045595 Phosphoprotein Phosphatases Human genes 0.000 claims abstract description 10
- 108700019535 Phosphoprotein Phosphatases Proteins 0.000 claims abstract description 10
- 238000002165 resonance energy transfer Methods 0.000 claims abstract description 6
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 claims abstract description 5
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 claims abstract description 5
- 230000010287 polarization Effects 0.000 claims abstract description 5
- 102000040945 Transcription factor Human genes 0.000 claims abstract description 4
- 108091023040 Transcription factor Proteins 0.000 claims abstract description 4
- 108010003591 Cyclic GMP-Dependent Protein Kinases Proteins 0.000 claims abstract description 3
- 102000004654 Cyclic GMP-Dependent Protein Kinases Human genes 0.000 claims abstract description 3
- 239000003226 mitogen Substances 0.000 claims abstract description 3
- 150000003904 phospholipids Chemical class 0.000 claims abstract description 3
- 229940100514 Syk tyrosine kinase inhibitor Drugs 0.000 claims abstract 2
- 210000004027 cell Anatomy 0.000 claims description 256
- 230000004927 fusion Effects 0.000 claims description 95
- 108090000623 proteins and genes Proteins 0.000 claims description 75
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 69
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 63
- 229920001184 polypeptide Polymers 0.000 claims description 61
- 230000008859 change Effects 0.000 claims description 54
- 230000004044 response Effects 0.000 claims description 40
- 102000004169 proteins and genes Human genes 0.000 claims description 39
- 238000009826 distribution Methods 0.000 claims description 32
- 239000000126 substance Substances 0.000 claims description 23
- 230000003834 intracellular effect Effects 0.000 claims description 20
- 230000004807 localization Effects 0.000 claims description 18
- 101710199605 Endoribonuclease Proteins 0.000 claims description 17
- 101710113029 Serine/threonine-protein kinase Proteins 0.000 claims description 17
- 238000012545 processing Methods 0.000 claims description 16
- 230000008569 process Effects 0.000 claims description 15
- 229940079593 drug Drugs 0.000 claims description 13
- 239000003814 drug Substances 0.000 claims description 13
- 102000004190 Enzymes Human genes 0.000 claims description 12
- 108090000790 Enzymes Proteins 0.000 claims description 12
- 150000001413 amino acids Chemical group 0.000 claims description 11
- 210000004962 mammalian cell Anatomy 0.000 claims description 9
- 210000004292 cytoskeleton Anatomy 0.000 claims description 8
- 230000001965 increasing effect Effects 0.000 claims description 7
- 230000004071 biological effect Effects 0.000 claims description 6
- 230000036755 cellular response Effects 0.000 claims description 6
- 238000000799 fluorescence microscopy Methods 0.000 claims description 5
- 102000034287 fluorescent proteins Human genes 0.000 claims description 5
- 108091006047 fluorescent proteins Proteins 0.000 claims description 5
- 230000003436 cytoskeletal effect Effects 0.000 claims description 4
- 230000026731 phosphorylation Effects 0.000 claims description 4
- 238000006366 phosphorylation reaction Methods 0.000 claims description 4
- 238000011144 upstream manufacturing Methods 0.000 claims description 4
- 102000016736 Cyclin Human genes 0.000 claims description 3
- 108050006400 Cyclin Proteins 0.000 claims description 3
- 230000006662 intracellular pathway Effects 0.000 claims description 3
- 230000035772 mutation Effects 0.000 claims description 3
- 231100000167 toxic agent Toxicity 0.000 claims description 3
- 239000003440 toxic substance Substances 0.000 claims description 3
- 238000012546 transfer Methods 0.000 claims description 3
- 102000000584 Calmodulin Human genes 0.000 claims description 2
- 108010041952 Calmodulin Proteins 0.000 claims description 2
- 102000009097 Phosphorylases Human genes 0.000 claims description 2
- 108010073135 Phosphorylases Proteins 0.000 claims description 2
- 230000030609 dephosphorylation Effects 0.000 claims description 2
- 238000006209 dephosphorylation reaction Methods 0.000 claims description 2
- 239000004615 ingredient Substances 0.000 claims description 2
- 102100030011 Endoribonuclease Human genes 0.000 claims 5
- 102220054792 rs138065384 Human genes 0.000 claims 1
- 150000003355 serines Chemical class 0.000 claims 1
- 239000005090 green fluorescent protein Substances 0.000 abstract description 150
- 108010043121 Green Fluorescent Proteins Proteins 0.000 abstract description 75
- 102000004144 Green Fluorescent Proteins Human genes 0.000 abstract description 75
- 150000001875 compounds Chemical class 0.000 abstract description 33
- 108010048367 enhanced green fluorescent protein Proteins 0.000 abstract description 28
- 230000037361 pathway Effects 0.000 abstract description 16
- 238000005259 measurement Methods 0.000 abstract description 10
- 101000979342 Homo sapiens Nuclear factor NF-kappa-B p105 subunit Proteins 0.000 abstract description 9
- 101100268066 Mus musculus Zap70 gene Proteins 0.000 abstract description 9
- 102100023050 Nuclear factor NF-kappa-B p105 subunit Human genes 0.000 abstract description 9
- 201000010099 disease Diseases 0.000 abstract description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 7
- 108010068338 p38 Mitogen-Activated Protein Kinases Proteins 0.000 abstract description 7
- 102000002574 p38 Mitogen-Activated Protein Kinases Human genes 0.000 abstract description 7
- 101150101215 Mapk8 gene Proteins 0.000 abstract description 5
- 101710113459 RAC-alpha serine/threonine-protein kinase Proteins 0.000 abstract description 5
- 108010085238 Actins Proteins 0.000 abstract description 4
- 102000007469 Actins Human genes 0.000 abstract description 4
- 101100356682 Caenorhabditis elegans rho-1 gene Proteins 0.000 abstract description 4
- 102220566687 GDNF family receptor alpha-1_F64L_mutation Human genes 0.000 abstract description 4
- 101001046426 Homo sapiens cGMP-dependent protein kinase 1 Proteins 0.000 abstract description 4
- 101150111584 RHOA gene Proteins 0.000 abstract description 4
- 102000015792 Cyclin-Dependent Kinase 2 Human genes 0.000 abstract description 3
- 108010024986 Cyclin-Dependent Kinase 2 Proteins 0.000 abstract description 3
- 102220566469 GDNF family receptor alpha-1_S65T_mutation Human genes 0.000 abstract description 3
- 102100021164 Vasodilator-stimulated phosphoprotein Human genes 0.000 abstract description 3
- 230000002596 correlated effect Effects 0.000 abstract description 3
- 108010054220 vasodilator-stimulated phosphoprotein Proteins 0.000 abstract description 3
- 101150033606 Grk5 gene Proteins 0.000 abstract description 2
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 abstract description 2
- 108010015793 Non-Receptor Type 6 Protein Tyrosine Phosphatase Proteins 0.000 abstract description 2
- -1 PKA Proteins 0.000 abstract 3
- 101100366888 Dictyostelium discoideum dstA gene Proteins 0.000 abstract 1
- 101000652725 Drosophila melanogaster Transcription initiation factor TFIID subunit 5 Proteins 0.000 abstract 1
- 102220566451 GDNF family receptor alpha-1_Y66H_mutation Human genes 0.000 abstract 1
- 101000752722 Homo sapiens Apoptosis-stimulating of p53 protein 1 Proteins 0.000 abstract 1
- 101001120056 Homo sapiens Phosphatidylinositol 3-kinase regulatory subunit alpha Proteins 0.000 abstract 1
- 101001120097 Homo sapiens Phosphatidylinositol 3-kinase regulatory subunit beta Proteins 0.000 abstract 1
- 101001116549 Homo sapiens Protein CBFA2T2 Proteins 0.000 abstract 1
- 101001000998 Homo sapiens Protein phosphatase 1 regulatory subunit 12C Proteins 0.000 abstract 1
- 101000927796 Homo sapiens Rho guanine nucleotide exchange factor 7 Proteins 0.000 abstract 1
- 102000002001 Non-Receptor Type 6 Protein Tyrosine Phosphatase Human genes 0.000 abstract 1
- 230000004068 intracellular signaling Effects 0.000 abstract 1
- 125000003607 serino group Chemical class [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 abstract 1
- 229960002898 threonine Drugs 0.000 abstract 1
- 238000003752 polymerase chain reaction Methods 0.000 description 129
- 239000000523 sample Substances 0.000 description 96
- OHCQJHSOBUTRHG-KGGHGJDLSA-N FORSKOLIN Chemical compound O=C([C@@]12O)C[C@](C)(C=C)O[C@]1(C)[C@@H](OC(=O)C)[C@@H](O)[C@@H]1[C@]2(C)[C@@H](O)CCC1(C)C OHCQJHSOBUTRHG-KGGHGJDLSA-N 0.000 description 74
- 230000000694 effects Effects 0.000 description 54
- 239000000047 product Substances 0.000 description 53
- 239000013615 primer Substances 0.000 description 50
- 230000019491 signal transduction Effects 0.000 description 49
- 108091008146 restriction endonucleases Proteins 0.000 description 45
- 230000004913 activation Effects 0.000 description 44
- SUZLHDUTVMZSEV-UHFFFAOYSA-N Deoxycoleonol Natural products C12C(=O)CC(C)(C=C)OC2(C)C(OC(=O)C)C(O)C2C1(C)C(O)CCC2(C)C SUZLHDUTVMZSEV-UHFFFAOYSA-N 0.000 description 37
- 230000001413 cellular effect Effects 0.000 description 37
- OHCQJHSOBUTRHG-UHFFFAOYSA-N colforsin Natural products OC12C(=O)CC(C)(C=C)OC1(C)C(OC(=O)C)C(O)C1C2(C)C(O)CCC1(C)C OHCQJHSOBUTRHG-UHFFFAOYSA-N 0.000 description 37
- 150000007523 nucleic acids Chemical class 0.000 description 28
- 239000013612 plasmid Substances 0.000 description 28
- 230000005945 translocation Effects 0.000 description 27
- 230000001086 cytosolic effect Effects 0.000 description 26
- 238000001514 detection method Methods 0.000 description 26
- 238000002474 experimental method Methods 0.000 description 24
- 238000012544 monitoring process Methods 0.000 description 24
- 102000039446 nucleic acids Human genes 0.000 description 24
- 108020004707 nucleic acids Proteins 0.000 description 24
- 238000011282 treatment Methods 0.000 description 22
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 21
- 108020001507 fusion proteins Proteins 0.000 description 21
- 102000037865 fusion proteins Human genes 0.000 description 21
- 238000003556 assay Methods 0.000 description 19
- 238000012360 testing method Methods 0.000 description 18
- 108090000315 Protein Kinase C Proteins 0.000 description 17
- 102000003923 Protein Kinase C Human genes 0.000 description 17
- 239000000872 buffer Substances 0.000 description 16
- 230000014509 gene expression Effects 0.000 description 15
- 108040008097 MAP kinase activity proteins Proteins 0.000 description 14
- 102000019149 MAP kinase activity proteins Human genes 0.000 description 14
- 108091028043 Nucleic acid sequence Proteins 0.000 description 13
- 210000004940 nucleus Anatomy 0.000 description 13
- 108020004414 DNA Proteins 0.000 description 12
- 102100030013 Endoribonuclease Human genes 0.000 description 12
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 12
- 108091000080 Phosphotransferase Proteins 0.000 description 12
- 108010029485 Protein Isoforms Proteins 0.000 description 12
- 102000001708 Protein Isoforms Human genes 0.000 description 12
- 239000002609 medium Substances 0.000 description 12
- 210000000805 cytoplasm Anatomy 0.000 description 11
- 238000011002 quantification Methods 0.000 description 11
- 230000030570 cellular localization Effects 0.000 description 10
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 10
- 239000012528 membrane Substances 0.000 description 10
- 102000020233 phosphotransferase Human genes 0.000 description 10
- 210000001519 tissue Anatomy 0.000 description 10
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 9
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 9
- 238000013459 approach Methods 0.000 description 9
- 108020003175 receptors Proteins 0.000 description 9
- 210000002966 serum Anatomy 0.000 description 9
- 102000003676 Glucocorticoid Receptors Human genes 0.000 description 8
- 108090000079 Glucocorticoid Receptors Proteins 0.000 description 8
- 210000000170 cell membrane Anatomy 0.000 description 8
- 238000010367 cloning Methods 0.000 description 8
- 150000001982 diacylglycerols Chemical class 0.000 description 8
- 231100000673 dose–response relationship Toxicity 0.000 description 8
- 239000003102 growth factor Substances 0.000 description 8
- 230000006525 intracellular process Effects 0.000 description 8
- 238000004020 luminiscence type Methods 0.000 description 8
- 102000005962 receptors Human genes 0.000 description 8
- 230000000638 stimulation Effects 0.000 description 8
- 102000043136 MAP kinase family Human genes 0.000 description 7
- 108091054455 MAP kinase family Proteins 0.000 description 7
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 7
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 7
- 101000852815 Homo sapiens Insulin receptor Proteins 0.000 description 6
- 210000004899 c-terminal region Anatomy 0.000 description 6
- AIXAANGOTKPUOY-UHFFFAOYSA-N carbachol Chemical compound [Cl-].C[N+](C)(C)CCOC(N)=O AIXAANGOTKPUOY-UHFFFAOYSA-N 0.000 description 6
- 229960004484 carbachol Drugs 0.000 description 6
- 230000003197 catalytic effect Effects 0.000 description 6
- 238000010276 construction Methods 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 6
- 239000012091 fetal bovine serum Substances 0.000 description 6
- 102000047882 human INSR Human genes 0.000 description 6
- 108020001775 protein parts Proteins 0.000 description 6
- 230000001105 regulatory effect Effects 0.000 description 6
- 238000002821 scintillation proximity assay Methods 0.000 description 6
- 102000004127 Cytokines Human genes 0.000 description 5
- 108090000695 Cytokines Proteins 0.000 description 5
- 102000051325 Glucagon Human genes 0.000 description 5
- 108060003199 Glucagon Proteins 0.000 description 5
- 102000004877 Insulin Human genes 0.000 description 5
- 108090001061 Insulin Proteins 0.000 description 5
- 241001529936 Murinae Species 0.000 description 5
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 5
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 5
- 102000030621 adenylate cyclase Human genes 0.000 description 5
- 108060000200 adenylate cyclase Proteins 0.000 description 5
- 239000000556 agonist Substances 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 230000005284 excitation Effects 0.000 description 5
- 239000007850 fluorescent dye Substances 0.000 description 5
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 5
- 229960004666 glucagon Drugs 0.000 description 5
- 229940125396 insulin Drugs 0.000 description 5
- 238000002372 labelling Methods 0.000 description 5
- 239000002773 nucleotide Substances 0.000 description 5
- 125000003729 nucleotide group Chemical group 0.000 description 5
- 241000894007 species Species 0.000 description 5
- 239000013598 vector Substances 0.000 description 5
- YKJYKKNCCRKFSL-RDBSUJKOSA-N (-)-anisomycin Chemical compound C1=CC(OC)=CC=C1C[C@@H]1[C@H](OC(C)=O)[C@@H](O)CN1 YKJYKKNCCRKFSL-RDBSUJKOSA-N 0.000 description 4
- YKJYKKNCCRKFSL-UHFFFAOYSA-N Anisomycin Natural products C1=CC(OC)=CC=C1CC1C(OC(C)=O)C(O)CN1 YKJYKKNCCRKFSL-UHFFFAOYSA-N 0.000 description 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 4
- 102000058061 Glucose Transporter Type 4 Human genes 0.000 description 4
- 101150024075 Mapk1 gene Proteins 0.000 description 4
- 101710143112 Mothers against decapentaplegic homolog 4 Proteins 0.000 description 4
- 102100025725 Mothers against decapentaplegic homolog 4 Human genes 0.000 description 4
- 102100033810 RAC-alpha serine/threonine-protein kinase Human genes 0.000 description 4
- 108091006300 SLC2A4 Proteins 0.000 description 4
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 4
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 4
- 108010084455 Zeocin Proteins 0.000 description 4
- 230000003321 amplification Effects 0.000 description 4
- CJGYSWNGNKCJSB-YVLZZHOMSA-N bucladesine Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](OC(=O)CCC)[C@@H]2N1C(N=CN=C2NC(=O)CCC)=C2N=C1 CJGYSWNGNKCJSB-YVLZZHOMSA-N 0.000 description 4
- 229960005263 bucladesine Drugs 0.000 description 4
- 239000011575 calcium Substances 0.000 description 4
- 230000004637 cellular stress Effects 0.000 description 4
- 239000002299 complementary DNA Substances 0.000 description 4
- 239000013604 expression vector Substances 0.000 description 4
- 230000002068 genetic effect Effects 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- 238000003199 nucleic acid amplification method Methods 0.000 description 4
- 230000003287 optical effect Effects 0.000 description 4
- CWCMIVBLVUHDHK-ZSNHEYEWSA-N phleomycin D1 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC[C@@H](N=1)C=1SC=C(N=1)C(=O)NCCCCNC(N)=N)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C CWCMIVBLVUHDHK-ZSNHEYEWSA-N 0.000 description 4
- 230000008707 rearrangement Effects 0.000 description 4
- 229960005322 streptomycin Drugs 0.000 description 4
- ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 description 3
- 108020004705 Codon Proteins 0.000 description 3
- 102000053602 DNA Human genes 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 3
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 239000007995 HEPES buffer Substances 0.000 description 3
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 101710143123 Mothers against decapentaplegic homolog 2 Proteins 0.000 description 3
- 102100025751 Mothers against decapentaplegic homolog 2 Human genes 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 239000012190 activator Substances 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 238000003491 array Methods 0.000 description 3
- 230000008827 biological function Effects 0.000 description 3
- 102100022422 cGMP-dependent protein kinase 1 Human genes 0.000 description 3
- 239000001506 calcium phosphate Substances 0.000 description 3
- 229910000389 calcium phosphate Inorganic materials 0.000 description 3
- 235000011010 calcium phosphates Nutrition 0.000 description 3
- ZOOGRGPOEVQQDX-UHFFFAOYSA-N cyclic GMP Natural products O1C2COP(O)(=O)OC2C(O)C1N1C=NC2=C1NC(N)=NC2=O ZOOGRGPOEVQQDX-UHFFFAOYSA-N 0.000 description 3
- 230000009849 deactivation Effects 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 230000003511 endothelial effect Effects 0.000 description 3
- 239000012894 fetal calf serum Substances 0.000 description 3
- 210000001650 focal adhesion Anatomy 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 230000004190 glucose uptake Effects 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 230000002452 interceptive effect Effects 0.000 description 3
- 239000002547 new drug Substances 0.000 description 3
- PHEDXBVPIONUQT-RGYGYFBISA-N phorbol 13-acetate 12-myristate Chemical compound C([C@]1(O)C(=O)C(C)=C[C@H]1[C@@]1(O)[C@H](C)[C@H]2OC(=O)CCCCCCCCCCCCC)C(CO)=C[C@H]1[C@H]1[C@]2(OC(C)=O)C1(C)C PHEDXBVPIONUQT-RGYGYFBISA-N 0.000 description 3
- 230000007398 protein translocation Effects 0.000 description 3
- 238000001454 recorded image Methods 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 230000011664 signaling Effects 0.000 description 3
- 230000035882 stress Effects 0.000 description 3
- 108091006106 transcriptional activators Proteins 0.000 description 3
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 3
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 3
- 230000000007 visual effect Effects 0.000 description 3
- 238000012800 visualization Methods 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- 210000005253 yeast cell Anatomy 0.000 description 3
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 2
- 108060003345 Adrenergic Receptor Proteins 0.000 description 2
- 102000017910 Adrenergic receptor Human genes 0.000 description 2
- 241000242764 Aequorea victoria Species 0.000 description 2
- HJCMDXDYPOUFDY-WHFBIAKZSA-N Ala-Gln Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CCC(N)=O HJCMDXDYPOUFDY-WHFBIAKZSA-N 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 108020004635 Complementary DNA Proteins 0.000 description 2
- 241000699800 Cricetinae Species 0.000 description 2
- 102100031480 Dual specificity mitogen-activated protein kinase kinase 1 Human genes 0.000 description 2
- 101710146526 Dual specificity mitogen-activated protein kinase kinase 1 Proteins 0.000 description 2
- 102000007665 Extracellular Signal-Regulated MAP Kinases Human genes 0.000 description 2
- 108010007457 Extracellular Signal-Regulated MAP Kinases Proteins 0.000 description 2
- 108091006027 G proteins Proteins 0.000 description 2
- 102000030782 GTP binding Human genes 0.000 description 2
- 108091000058 GTP-Binding Proteins 0.000 description 2
- 108010063919 Glucagon Receptors Proteins 0.000 description 2
- 102100040890 Glucagon receptor Human genes 0.000 description 2
- 108050002220 Green fluorescent protein, GFP Proteins 0.000 description 2
- 241000238631 Hexapoda Species 0.000 description 2
- 101000919320 Homo sapiens Adapter molecule crk Proteins 0.000 description 2
- 101100005781 Homo sapiens CDK2 gene Proteins 0.000 description 2
- 101100015816 Homo sapiens GRK5 gene Proteins 0.000 description 2
- 101001051777 Homo sapiens Protein kinase C alpha type Proteins 0.000 description 2
- 101000779418 Homo sapiens RAC-alpha serine/threonine-protein kinase Proteins 0.000 description 2
- 101100533704 Homo sapiens SMAD2 gene Proteins 0.000 description 2
- 101100533714 Homo sapiens SMAD4 gene Proteins 0.000 description 2
- 101000946860 Homo sapiens T-cell surface glycoprotein CD3 epsilon chain Proteins 0.000 description 2
- 101000617285 Homo sapiens Tyrosine-protein phosphatase non-receptor type 6 Proteins 0.000 description 2
- 102000008072 Lymphokines Human genes 0.000 description 2
- 108010074338 Lymphokines Proteins 0.000 description 2
- 229940124647 MEK inhibitor Drugs 0.000 description 2
- 239000012820 MEK1 Inhibitor Substances 0.000 description 2
- 108010040897 Microfilament Proteins Proteins 0.000 description 2
- 102000002151 Microfilament Proteins Human genes 0.000 description 2
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
- 101150019648 PKG gene Proteins 0.000 description 2
- 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 description 2
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 description 2
- 102100024924 Protein kinase C alpha type Human genes 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 101100345684 Rattus norvegicus Mapk1 gene Proteins 0.000 description 2
- 108091008874 T cell receptors Proteins 0.000 description 2
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 2
- 102100035794 T-cell surface glycoprotein CD3 epsilon chain Human genes 0.000 description 2
- 102000043168 TGF-beta family Human genes 0.000 description 2
- 108091085018 TGF-beta family Proteins 0.000 description 2
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 238000000137 annealing Methods 0.000 description 2
- 238000003705 background correction Methods 0.000 description 2
- 239000007975 buffered saline Substances 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000022131 cell cycle Effects 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000000875 corresponding effect Effects 0.000 description 2
- 238000004132 cross linking Methods 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 239000003596 drug target Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 238000002073 fluorescence micrograph Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 238000011990 functional testing Methods 0.000 description 2
- 230000002538 fungal effect Effects 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 229910001385 heavy metal Inorganic materials 0.000 description 2
- 235000003642 hunger Nutrition 0.000 description 2
- 238000005286 illumination Methods 0.000 description 2
- 238000007654 immersion Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 239000000411 inducer Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000033001 locomotion Effects 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 229960002748 norepinephrine Drugs 0.000 description 2
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 2
- 230000005937 nuclear translocation Effects 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000007423 screening assay Methods 0.000 description 2
- 230000008054 signal transmission Effects 0.000 description 2
- 230000037351 starvation Effects 0.000 description 2
- 238000012144 step-by-step procedure Methods 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 230000004960 subcellular localization Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000036962 time dependent Effects 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 230000009261 transgenic effect Effects 0.000 description 2
- 230000001052 transient effect Effects 0.000 description 2
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 108091006112 ATPases Proteins 0.000 description 1
- 108010063503 Actinin Proteins 0.000 description 1
- 102000057290 Adenosine Triphosphatases Human genes 0.000 description 1
- 241000243290 Aequorea Species 0.000 description 1
- 241000195940 Bryophyta Species 0.000 description 1
- 102000017927 CHRM1 Human genes 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 101150073075 Chrm1 gene Proteins 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- 241000195493 Cryptophyta Species 0.000 description 1
- 239000003155 DNA primer Substances 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000018711 Facilitative Glucose Transport Proteins Human genes 0.000 description 1
- 102100023374 Forkhead box protein M1 Human genes 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 102100023685 G protein-coupled receptor kinase 5 Human genes 0.000 description 1
- 108010008959 G-Protein-Coupled Receptor Kinases Proteins 0.000 description 1
- 102000006575 G-Protein-Coupled Receptor Kinases Human genes 0.000 description 1
- 108091005973 GFP derivatives Proteins 0.000 description 1
- 101150066002 GFP gene Proteins 0.000 description 1
- 102000013446 GTP Phosphohydrolases Human genes 0.000 description 1
- 108091006109 GTPases Proteins 0.000 description 1
- 108091052347 Glucose transporter family Proteins 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 108010078321 Guanylate Cyclase Proteins 0.000 description 1
- 102000014469 Guanylate cyclase Human genes 0.000 description 1
- 101000907578 Homo sapiens Forkhead box protein M1 Proteins 0.000 description 1
- 101000829476 Homo sapiens G protein-coupled receptor kinase 5 Proteins 0.000 description 1
- 101001040075 Homo sapiens Glucagon receptor Proteins 0.000 description 1
- 101001052490 Homo sapiens Mitogen-activated protein kinase 3 Proteins 0.000 description 1
- 101000995104 Homo sapiens Nuclear factor of activated T-cells, cytoplasmic 2 Proteins 0.000 description 1
- 101001026864 Homo sapiens Protein kinase C gamma type Proteins 0.000 description 1
- 101100468710 Homo sapiens RHOA gene Proteins 0.000 description 1
- 101001059454 Homo sapiens Serine/threonine-protein kinase MARK2 Proteins 0.000 description 1
- 101001087416 Homo sapiens Tyrosine-protein phosphatase non-receptor type 11 Proteins 0.000 description 1
- 101100049064 Homo sapiens VASP gene Proteins 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- BZQFBWGGLXLEPQ-UHFFFAOYSA-N O-phosphoryl-L-serine Natural products OC(=O)C(N)COP(O)(O)=O BZQFBWGGLXLEPQ-UHFFFAOYSA-N 0.000 description 1
- 229940099471 Phosphodiesterase inhibitor Drugs 0.000 description 1
- 102000015439 Phospholipases Human genes 0.000 description 1
- 108010064785 Phospholipases Proteins 0.000 description 1
- 108010089430 Phosphoproteins Proteins 0.000 description 1
- 102000007982 Phosphoproteins Human genes 0.000 description 1
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 1
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 1
- 102000003946 Prolactin Human genes 0.000 description 1
- 108010057464 Prolactin Proteins 0.000 description 1
- 108010001267 Protein Subunits Proteins 0.000 description 1
- 102000002067 Protein Subunits Human genes 0.000 description 1
- 102000002727 Protein Tyrosine Phosphatase Human genes 0.000 description 1
- 102100037314 Protein kinase C gamma type Human genes 0.000 description 1
- 102000004278 Receptor Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000873 Receptor Protein-Tyrosine Kinases Proteins 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- 241000242583 Scyphozoa Species 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 102100028904 Serine/threonine-protein kinase MARK2 Human genes 0.000 description 1
- 102000005157 Somatostatin Human genes 0.000 description 1
- 108010056088 Somatostatin Proteins 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 108010022394 Threonine synthase Proteins 0.000 description 1
- 241000592342 Tracheophyta Species 0.000 description 1
- 108700019146 Transgenes Proteins 0.000 description 1
- 102100033019 Tyrosine-protein phosphatase non-receptor type 11 Human genes 0.000 description 1
- 102100021657 Tyrosine-protein phosphatase non-receptor type 6 Human genes 0.000 description 1
- 108091005971 Wild-type GFP Proteins 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 238000013528 artificial neural network Methods 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000033077 cellular process Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 239000013599 cloning vector Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 239000006059 cover glass Substances 0.000 description 1
- 230000007711 cytoplasmic localization Effects 0.000 description 1
- 210000000172 cytosol Anatomy 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 238000000586 desensitisation Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- 229950006137 dexfosfoserine Drugs 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 102000004419 dihydrofolate reductase Human genes 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 108010093406 dopamine D1A receptor Proteins 0.000 description 1
- 238000003708 edge detection Methods 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000007824 enzymatic assay Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000000834 fixative Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 238000002866 fluorescence resonance energy transfer Methods 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 150000002303 glucose derivatives Chemical class 0.000 description 1
- 238000009499 grossing Methods 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 210000004754 hybrid cell Anatomy 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 238000010191 image analysis Methods 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000003365 immunocytochemistry Methods 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 238000012804 iterative process Methods 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 210000003632 microfilament Anatomy 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 230000003551 muscarinic effect Effects 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 239000006225 natural substrate Substances 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 230000000955 neuroendocrine Effects 0.000 description 1
- 210000004492 nuclear pore Anatomy 0.000 description 1
- 230000030648 nucleus localization Effects 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 238000003909 pattern recognition Methods 0.000 description 1
- 230000008823 permeabilization Effects 0.000 description 1
- 239000002571 phosphodiesterase inhibitor Substances 0.000 description 1
- BZQFBWGGLXLEPQ-REOHCLBHSA-N phosphoserine Chemical compound OC(=O)[C@@H](N)COP(O)(O)=O BZQFBWGGLXLEPQ-REOHCLBHSA-N 0.000 description 1
- USRGIUJOYOXOQJ-GBXIJSLDSA-N phosphothreonine Chemical compound OP(=O)(O)O[C@H](C)[C@H](N)C(O)=O USRGIUJOYOXOQJ-GBXIJSLDSA-N 0.000 description 1
- DCWXELXMIBXGTH-UHFFFAOYSA-N phosphotyrosine Chemical compound OC(=O)C(N)CC1=CC=C(OP(O)(O)=O)C=C1 DCWXELXMIBXGTH-UHFFFAOYSA-N 0.000 description 1
- 230000008560 physiological behavior Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 230000034190 positive regulation of NF-kappaB transcription factor activity Effects 0.000 description 1
- 230000003478 prestimulatory effect Effects 0.000 description 1
- 229940097325 prolactin Drugs 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 108020000494 protein-tyrosine phosphatase Proteins 0.000 description 1
- 210000001147 pulmonary artery Anatomy 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 238000012207 quantitative assay Methods 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 238000001525 receptor binding assay Methods 0.000 description 1
- 238000002777 redistribution assay Methods 0.000 description 1
- 230000027425 release of sequestered calcium ion into cytosol Effects 0.000 description 1
- 238000003571 reporter gene assay Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 150000003354 serine derivatives Chemical class 0.000 description 1
- 102000030938 small GTPase Human genes 0.000 description 1
- 108060007624 small GTPase Proteins 0.000 description 1
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 description 1
- 229960000553 somatostatin Drugs 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 210000003518 stress fiber Anatomy 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000001954 time-lapse fluorescence microscopy Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000003151 transfection method Methods 0.000 description 1
- 239000012096 transfection reagent Substances 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 230000014621 translational initiation Effects 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 238000009827 uniform distribution Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
- G01N33/5041—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving analysis of members of signalling pathways
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
- G01N33/5035—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on sub-cellular localization
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/531—Production of immunochemical test materials
- G01N33/532—Production of labelled immunochemicals
- G01N33/533—Production of labelled immunochemicals with fluorescent label
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
- G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/43504—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from invertebrates
- G01N2333/43595—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from invertebrates from coelenteratae, e.g. medusae
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/91—Transferases (2.)
- G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- G01N2333/91205—Phosphotransferases in general
- G01N2333/9121—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Toxicology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
- Analysing Materials By The Use Of Radiation (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DK39297 | 1997-04-07 | ||
| DK39297 | 1997-04-07 | ||
| PCT/DK1998/000145 WO1998045704A2 (en) | 1997-04-07 | 1998-04-07 | A method for extracting quantitative information relating to an influence on a cellular response |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| DE69804446D1 DE69804446D1 (de) | 2002-05-02 |
| DE69804446T2 DE69804446T2 (de) | 2002-11-07 |
| DE69804446T3 true DE69804446T3 (de) | 2006-08-24 |
Family
ID=8092994
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE69804446T Expired - Fee Related DE69804446T3 (de) | 1997-04-07 | 1998-04-07 | Verfahren um quantitativen informationen über einflüsse auf zelluläre reaktionen zu entnehmen |
| DE69824763T Expired - Lifetime DE69824763T2 (de) | 1997-04-07 | 1998-04-07 | Verfahren zum Screenen von Substanzen die einen effekt auf intrazelluläre Translokation haben |
| DE1199564T Pending DE1199564T1 (de) | 1997-04-07 | 1998-04-07 | Verfahren zum Screenen von Substanzen die einen effekt auf intrazelluläre Translokation haben |
| DE69837118T Expired - Fee Related DE69837118T2 (de) | 1997-04-07 | 1998-04-07 | Ein Verfahren zum Screenen von Substanzen hinsichtlich ihres Effekts auf cAMP Spiegel basierend auf intrazellulärer Translokation von PKA |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE69824763T Expired - Lifetime DE69824763T2 (de) | 1997-04-07 | 1998-04-07 | Verfahren zum Screenen von Substanzen die einen effekt auf intrazelluläre Translokation haben |
| DE1199564T Pending DE1199564T1 (de) | 1997-04-07 | 1998-04-07 | Verfahren zum Screenen von Substanzen die einen effekt auf intrazelluläre Translokation haben |
| DE69837118T Expired - Fee Related DE69837118T2 (de) | 1997-04-07 | 1998-04-07 | Ein Verfahren zum Screenen von Substanzen hinsichtlich ihres Effekts auf cAMP Spiegel basierend auf intrazellulärer Translokation von PKA |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US6518021B1 (https=) |
| EP (3) | EP1435519B1 (https=) |
| JP (1) | JP2001522454A (https=) |
| AT (3) | ATE215227T1 (https=) |
| AU (1) | AU6820998A (https=) |
| CA (1) | CA2286293C (https=) |
| DE (4) | DE69804446T3 (https=) |
| DK (2) | DK1435519T3 (https=) |
| ES (2) | ES2191575T3 (https=) |
| PT (2) | PT1199564E (https=) |
| WO (1) | WO1998045704A2 (https=) |
Families Citing this family (85)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100495690B1 (ko) | 1996-01-26 | 2005-11-08 | 비르코 비브이비에이 | 인체 hiv 계통의 표현형적 약제 감수성에 기초한 하나 이상의 최적한 hiv 저해제를 선발하는 방법 |
| US7062219B2 (en) * | 1997-01-31 | 2006-06-13 | Odyssey Thera Inc. | Protein fragment complementation assays for high-throughput and high-content screening |
| US6759206B1 (en) | 1997-02-27 | 2004-07-06 | Cellomics, Inc. | System for cell-based screening |
| US6416959B1 (en) | 1997-02-27 | 2002-07-09 | Kenneth Giuliano | System for cell-based screening |
| US7853411B2 (en) | 1997-02-27 | 2010-12-14 | Cellomics, Inc. | System for cell-based screening |
| DE69804446T3 (de) * | 1997-04-07 | 2006-08-24 | Bioimage A/S | Verfahren um quantitativen informationen über einflüsse auf zelluläre reaktionen zu entnehmen |
| US7160687B1 (en) | 1997-05-29 | 2007-01-09 | Cellomics, Inc. | Miniaturized cell array methods and apparatus for cell-based screening |
| US6235512B1 (en) * | 1997-07-01 | 2001-05-22 | Tularik Inc. | IKK-α proteins, nucleic acids and methods |
| US20050221280A1 (en) | 1998-02-02 | 2005-10-06 | Odyssey Thera, Inc. | Protein-protein interactions for pharmacological profiling |
| US20030036855A1 (en) | 1998-03-16 | 2003-02-20 | Praelux Incorporated, A Corporation Of New Jersey | Method and apparatus for screening chemical compounds |
| US6388788B1 (en) | 1998-03-16 | 2002-05-14 | Praelux, Inc. | Method and apparatus for screening chemical compounds |
| JP2002507410A (ja) * | 1998-03-27 | 2002-03-12 | プロルーム・リミテッド | ルシフェラーゼ、蛍光タンパク質、ルシフェラーゼおよび蛍光タンパク質をコードする核酸および、診断、高処理スクリーニングおよび新規アイテムにおけるその使用 |
| US6037133A (en) * | 1998-04-17 | 2000-03-14 | Clontech Laboratories, Inc. | IκBEGFP constructs, cell lines and methods of use |
| US8680059B2 (en) * | 1998-05-20 | 2014-03-25 | Biotempt B.V. | Oligopeptide acetate and formulations thereof |
| US6844315B2 (en) * | 1998-05-20 | 2005-01-18 | Erasmus Universiteit Rotterdam | Immunoregulator |
| US20030220258A1 (en) | 2001-12-21 | 2003-11-27 | Robbert Benner | Treatment of ischemic events |
| EP1121593A2 (en) * | 1998-10-15 | 2001-08-08 | BioImage A/S | Method for extracting quantitative information relating to an influence on a cellular response |
| JP2003526608A (ja) * | 1998-10-15 | 2003-09-09 | バイオイメージ エイ／エス | 再分布及び／又は標的化での干渉によって得られる特異的治療の介入 |
| GB9901072D0 (en) * | 1999-01-19 | 1999-03-10 | Imp Cancer Res Tech | Methods for detecting changes to a macromolecular component of a cell |
| ATE239907T1 (de) * | 1999-02-26 | 2003-05-15 | Cellomics Inc | Ein system für zellbasierte reihenuntersuchungen |
| DE19915310A1 (de) * | 1999-04-03 | 2000-10-05 | Bayer Ag | Diffusionskontrollierende Sensorschicht |
| DE69906253D1 (de) * | 1999-04-29 | 2003-04-30 | Univ Erasmus | Bestimmung von Analytbeweglichkeit |
| US7151847B2 (en) | 2001-02-20 | 2006-12-19 | Cytokinetics, Inc. | Image analysis of the golgi complex |
| US6651008B1 (en) | 1999-05-14 | 2003-11-18 | Cytokinetics, Inc. | Database system including computer code for predictive cellular bioinformatics |
| US6743576B1 (en) | 1999-05-14 | 2004-06-01 | Cytokinetics, Inc. | Database system for predictive cellular bioinformatics |
| WO2000070528A2 (en) * | 1999-05-14 | 2000-11-23 | Cytokinetics, Inc. | Method and apparatus for predictive cellular bioinformatics |
| US20030228565A1 (en) * | 2000-04-26 | 2003-12-11 | Cytokinetics, Inc. | Method and apparatus for predictive cellular bioinformatics |
| EP1055929A1 (en) | 1999-05-26 | 2000-11-29 | Tibotec N.V. | Means and methods for drug discovery and the phenotypic characterisation of cells |
| US6573059B1 (en) * | 1999-06-04 | 2003-06-03 | Rmf Dictagene S.A. | Use of the regulatory subunit of the camp dependent protein kinase (PKA) from dictyostelium for camp measurements |
| WO2000075662A1 (en) * | 1999-06-09 | 2000-12-14 | Ljl Biosystems, Inc. | Cell-signaling assays |
| US6673554B1 (en) | 1999-06-14 | 2004-01-06 | Trellie Bioinformatics, Inc. | Protein localization assays for toxicity and antidotes thereto |
| AU7131900A (en) * | 1999-06-21 | 2001-01-09 | Cellomics, Inc. | A system for cell-based screening |
| US6121047A (en) * | 1999-07-21 | 2000-09-19 | Isis Pharmaceuticals Inc. | Antisense modulation of SHP-1 expression |
| US6489151B1 (en) * | 2000-03-27 | 2002-12-03 | The Research Foundation Of State University Of New York | Biologically active alternative form of the IKKα IκB kinase |
| EP1300418A1 (en) * | 2001-10-04 | 2003-04-09 | Erasmus Universiteit Rotterdam | Gene regulation by oligopeptides |
| KR100414641B1 (ko) * | 2000-04-07 | 2004-01-13 | 동부한농화학 주식회사 | 형질전환식물체의 생체분석방법 및 그를 이용한 시스템 |
| AU2001250286A1 (en) * | 2000-04-17 | 2001-10-30 | Bioimage A/S | Live cell procedures to identify compounds modulating intracellular distributionof phosphodiesterase (pde) enzymes |
| JP2003532077A (ja) * | 2000-04-26 | 2003-10-28 | バイオイメージ エイ／エス | 薬剤スクリーニング用の動的強度−べースの細胞内タンパク質−及び蛍光団−ベースの再分布アッセイについての化学シグナル増強 |
| AU2001270126A1 (en) * | 2000-06-23 | 2002-01-08 | Cytokinetics, Inc. | Image analysis for phenotyping sets of mutant cells |
| CA2414626A1 (en) * | 2000-07-04 | 2002-01-10 | Bioimage A/S | A method for extracting quantitative information relating to interactions between cellular components |
| US7625951B2 (en) | 2000-07-13 | 2009-12-01 | University Of Kentucky Research Foundation | Stimuli-responsive hydrogel microdomes integrated with genetically engineered proteins for high-throughput screening of pharmaceuticals |
| DE10037759A1 (de) * | 2000-08-03 | 2002-07-04 | Gruenenthal Gmbh | Screeningverfahren |
| KR100414781B1 (ko) * | 2000-11-24 | 2004-01-13 | 재단법인서울대학교산학협력재단 | ＮＦ-κＢ 발현을 인간 피부세포에서 정량적으로 측정하기위한 안정한 분석시스템 및 그의 용도 |
| US7218764B2 (en) | 2000-12-04 | 2007-05-15 | Cytokinetics, Inc. | Ploidy classification method |
| US6956961B2 (en) | 2001-02-20 | 2005-10-18 | Cytokinetics, Inc. | Extracting shape information contained in cell images |
| US7016787B2 (en) | 2001-02-20 | 2006-03-21 | Cytokinetics, Inc. | Characterizing biological stimuli by response curves |
| US7033790B2 (en) | 2001-04-03 | 2006-04-25 | Curagen Corporation | Proteins and nucleic acids encoding same |
| EP1499885B1 (en) | 2001-08-01 | 2009-10-21 | Cellomics, Inc. | Novel fusion proteins and assays for molecular binding |
| AU2002358657A1 (en) * | 2001-12-10 | 2003-06-23 | Evotec Oai Ag | Method for determining the influence of non-physiological compounds the derivatives and decomposition products thereof on organisms organs and cells |
| US7176303B2 (en) * | 2003-11-06 | 2007-02-13 | Isis Pharmaceuticals, Inc. | Modulation of STAT5 expression |
| US20030220257A1 (en) * | 2001-12-21 | 2003-11-27 | Robbert Benner | Treatment of trauma |
| US7560433B2 (en) | 2001-12-21 | 2009-07-14 | Biotempt B.V. | Treatment of multiple sclerosis (MS) |
| US7786084B2 (en) * | 2001-12-21 | 2010-08-31 | Biotempt B.V. | Treatment of burns |
| US20080242837A1 (en) * | 2001-12-21 | 2008-10-02 | Khan Nisar A | Peptide compositions |
| US20080318871A1 (en) * | 2001-12-21 | 2008-12-25 | Khan Nisar A | Treatment of neurological disorders |
| CA2413475C (en) | 2002-04-25 | 2010-07-27 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Zap-70 expression as a marker for chronic lymphocytic leukemia/small lymphocytic lymphoma (cll/sll) |
| GB0216674D0 (en) * | 2002-07-18 | 2002-08-28 | Amersham Biosciences Uk Ltd | Functional screening method |
| US8168568B1 (en) | 2003-03-10 | 2012-05-01 | The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | Combinatorial therapy for protein signaling diseases |
| US20050014217A1 (en) | 2003-07-18 | 2005-01-20 | Cytokinetics, Inc. | Predicting hepatotoxicity using cell based assays |
| GB2423988A (en) | 2003-07-18 | 2006-09-13 | Cytokinetics Inc | Characterizing biological stimuli by response curves |
| US7235353B2 (en) | 2003-07-18 | 2007-06-26 | Cytokinetics, Inc. | Predicting hepatotoxicity using cell based assays |
| US20050060100A1 (en) * | 2003-09-15 | 2005-03-17 | Becton Dickinson And Company | Computer software and algorithms for systems biologically linked to cellular phenotype |
| US20050059083A1 (en) * | 2003-09-15 | 2005-03-17 | Becton Dickinson And Company | High throughput method to identify ligands for cell attachment |
| US20090227505A1 (en) * | 2004-01-07 | 2009-09-10 | Biotempt B.V. | Methods and uses for protein breakdown products |
| EP2400030B1 (en) | 2004-05-18 | 2016-01-20 | The Board of Trustees of the Leland Stanford Junior University | Detection of protein translocation by beta-galactosidase reporter fragment complementation |
| US7323318B2 (en) | 2004-07-15 | 2008-01-29 | Cytokinetics, Inc. | Assay for distinguishing live and dead cells |
| US8084260B2 (en) * | 2004-11-24 | 2011-12-27 | Applied Biosystems, Llc | Spectral calibration method and system for multiple instruments |
| JP4846799B2 (ja) * | 2005-07-05 | 2011-12-28 | バイオテンプト ベー．フェー． | 腫瘍の治療 |
| EP1941044A2 (en) * | 2005-10-28 | 2008-07-09 | GE Healthcare UK Limited | Cell-based p38 mapk translocation assay |
| US20090170091A1 (en) * | 2006-01-17 | 2009-07-02 | Kenneth Giuliano | Method For Predicting Biological Systems Responses |
| EP1864692A1 (en) * | 2006-06-07 | 2007-12-12 | Biotempt B.V. | Use of peptides for the control of radiation injury |
| EP2027465A2 (en) | 2006-05-17 | 2009-02-25 | Cellumen, Inc. | Method for automated tissue analysis |
| WO2008060483A2 (en) * | 2006-11-10 | 2008-05-22 | Cellumen, Inc. | Protein-protein interaction biosensors and methods of use thereof |
| US20100178652A1 (en) * | 2007-01-05 | 2010-07-15 | Litherland Sally A | Materials and Methods for the Detection, Prevention and Treatment of Autoimmune Disease |
| DK2120991T3 (da) * | 2007-02-12 | 2014-04-28 | Biotempt Bv | Behandling af traumatisk blødning med korte oligopeptider |
| US20080217002A1 (en) * | 2007-03-07 | 2008-09-11 | Floyd Randolph Simonds | Sand control screen having a micro-perforated filtration layer |
| JP5438962B2 (ja) * | 2008-12-25 | 2014-03-12 | シスメックス株式会社 | 細胞画像表示装置 |
| US8574837B2 (en) | 2008-12-29 | 2013-11-05 | President And Fellows Of Harvard College | System for screening agonists/antagonists of cellular signaling pathways |
| KR101088605B1 (ko) | 2009-06-30 | 2011-11-30 | 한국산업기술대학교산학협력단 | 2대의 카메라를 이용한 세포 조작 방법 |
| JP5089713B2 (ja) * | 2010-01-18 | 2012-12-05 | シャープ株式会社 | 画像圧縮装置、圧縮画像出力装置、画像圧縮方法、コンピュータプログラム及び記録媒体 |
| US10018631B2 (en) | 2011-03-17 | 2018-07-10 | Cernostics, Inc. | Systems and compositions for diagnosing Barrett's esophagus and methods of using the same |
| EP2825887A4 (en) | 2012-03-15 | 2015-08-19 | Montana Molecular Llc | GENETICALLY-CODED, FLUORESCENT SENSORS FOR THE DETECTION OF INTRA-CELLULAR SIGNALS BY DIACYLGLYCEROL SIGNAL PATHS |
| EP2682187B1 (en) * | 2012-07-02 | 2017-09-13 | Molecular Devices, LLC | Selection method and apparatus |
| US11366114B2 (en) | 2013-11-04 | 2022-06-21 | Montana Molecular Llc | Genetically encoded fluorescent sensors for detecting ligand bias and intracellular signaling through cAMP pathways |
| DE102014012130B3 (de) | 2014-08-13 | 2015-03-05 | Alfred-Wegener-Institut, Helmholtz-Zentrum für Polar- und Meeresforschung | Nachweisverfahren unter Verwendung von rekombinanten lebenden Zellen zum Nachweis von xenobiotischen Stoffen sowie Anordnung und Testkit zur Durchführung des Nachweisverfahrens |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AT321257B (de) | 1971-05-26 | 1975-03-25 | Koreska Gmbh W | Anlage zur Rückgewinnung flüchtiger Lösungsmittel |
| JPS57198544A (en) * | 1981-05-28 | 1982-12-06 | Sony Corp | Manufacture of magnetic recording medium |
| DE3240063A1 (de) | 1981-11-02 | 1983-05-26 | Basf Ag, 6700 Ludwigshafen | Vorrichtung zur herstellung eines magnetogrammtraegers |
| JPS5880136A (ja) * | 1981-11-02 | 1983-05-14 | Fuji Photo Film Co Ltd | 磁気記録材料の製造方法 |
| JPH0656656B2 (ja) * | 1983-10-03 | 1994-07-27 | 富士写真フイルム株式会社 | 磁気記録媒体の製造方法 |
| JPS6292132A (ja) * | 1985-10-18 | 1987-04-27 | Fuji Photo Film Co Ltd | 磁気記録媒体の製造方法 |
| US4923766A (en) * | 1988-03-29 | 1990-05-08 | Canon Kabushiki Kaisha | Process for preparing magnetic recording |
| GB8916806D0 (en) * | 1989-07-22 | 1989-09-06 | Univ Wales Medicine | Modified proteins |
| DE4009797A1 (de) * | 1990-03-27 | 1991-10-02 | Pagendarm Gmbh | Verfahren und anordnung zum kondensieren von dampffoermigen substanzen |
| JPH09501302A (ja) * | 1993-04-07 | 1997-02-10 | キャンサー リサーチ キャンペーン テクノロジー リミティド | 治療活性についての物質のスクリーニングのための方法及びそれにおいて利用するための方法 |
| EP0759170B1 (en) * | 1993-09-10 | 2008-07-09 | The Trustees Of Columbia University In The City Of New York | Uses of green fluorescent protein |
| US6184205B1 (en) * | 1994-07-22 | 2001-02-06 | University Of North Carolina At Chapel Hill | GRB2 SH3 binding peptides and methods of isolating and using same |
| DE69534920T2 (de) * | 1994-07-22 | 2007-04-05 | University Of North Carolina | Src SH3 BINDENDE PEPTIDE UND VERFAHREN ZU IHRER ISOLIERUNG UND VERWENDUNG |
| US5874231A (en) * | 1994-08-22 | 1999-02-23 | Mcgill University | Methods of screening for non-hormone compounds which effect modulation of polypeptide translation |
| US5958713A (en) | 1995-01-31 | 1999-09-28 | Novo Nordisk A/S | Method of detecting biologically active substances by using green fluorescent protein |
| DK0815257T3 (da) * | 1995-01-31 | 2002-04-22 | Bioimage As | Fremgangsmåde til karakterisering af biologisk aktive stoffer |
| ATE184613T1 (de) * | 1995-09-22 | 1999-10-15 | Novo Nordisk As | Varianten des grünen fluoreszenzproteins, gfp |
| US6455300B1 (en) * | 1995-12-08 | 2002-09-24 | Han Htun | Method and compositions for monitoring DNA binding molecules in living cells |
| US5874304A (en) * | 1996-01-18 | 1999-02-23 | University Of Florida Research Foundation, Inc. | Humanized green fluorescent protein genes and methods |
| US5989835A (en) * | 1997-02-27 | 1999-11-23 | Cellomics, Inc. | System for cell-based screening |
| WO1998002571A1 (en) * | 1996-07-16 | 1998-01-22 | The Regents Of The University Of California | Assays for protein kinases using fluorescent protein substrates |
| AU5090498A (en) * | 1997-01-07 | 1998-08-03 | California Institute Of Technology | Optical sensors of cell signaling |
| CA2282658C (en) * | 1997-02-27 | 2003-02-25 | Cellomics, Inc. | A system for cell-based screening |
| US6416959B1 (en) * | 1997-02-27 | 2002-07-09 | Kenneth Giuliano | System for cell-based screening |
| DE69804446T3 (de) * | 1997-04-07 | 2006-08-24 | Bioimage A/S | Verfahren um quantitativen informationen über einflüsse auf zelluläre reaktionen zu entnehmen |
| WO2000049183A1 (en) * | 1999-02-17 | 2000-08-24 | Clontech Laboratories, Inc. | FLUORESCENCE RESONANCE ENERGY TRANSFER DETECTION OF cAMP IN LIVING CELLS USING GFP VARIANTS |
| US6573059B1 (en) * | 1999-06-04 | 2003-06-03 | Rmf Dictagene S.A. | Use of the regulatory subunit of the camp dependent protein kinase (PKA) from dictyostelium for camp measurements |
-
1998
- 1998-04-07 DE DE69804446T patent/DE69804446T3/de not_active Expired - Fee Related
- 1998-04-07 DK DK03028919T patent/DK1435519T3/da active
- 1998-04-07 DE DE69824763T patent/DE69824763T2/de not_active Expired - Lifetime
- 1998-04-07 AT AT98913541T patent/ATE215227T1/de not_active IP Right Cessation
- 1998-04-07 DK DK98913541T patent/DK0986753T4/da active
- 1998-04-07 AT AT01204477T patent/ATE269975T1/de not_active IP Right Cessation
- 1998-04-07 EP EP03028919A patent/EP1435519B1/en not_active Expired - Lifetime
- 1998-04-07 PT PT01204477T patent/PT1199564E/pt unknown
- 1998-04-07 DE DE1199564T patent/DE1199564T1/de active Pending
- 1998-04-07 CA CA002286293A patent/CA2286293C/en not_active Expired - Lifetime
- 1998-04-07 ES ES01204477T patent/ES2191575T3/es not_active Expired - Lifetime
- 1998-04-07 DE DE69837118T patent/DE69837118T2/de not_active Expired - Fee Related
- 1998-04-07 AT AT03028919T patent/ATE354089T1/de not_active IP Right Cessation
- 1998-04-07 ES ES98913541T patent/ES2173573T5/es not_active Expired - Lifetime
- 1998-04-07 EP EP98913541A patent/EP0986753B2/en not_active Expired - Lifetime
- 1998-04-07 WO PCT/DK1998/000145 patent/WO1998045704A2/en not_active Ceased
- 1998-04-07 AU AU68209/98A patent/AU6820998A/en not_active Abandoned
- 1998-04-07 EP EP01204477A patent/EP1199564B1/en not_active Expired - Lifetime
- 1998-04-07 JP JP54227698A patent/JP2001522454A/ja active Pending
- 1998-04-07 PT PT98913541T patent/PT986753E/pt unknown
-
1999
- 1999-10-07 US US09/417,197 patent/US6518021B1/en not_active Expired - Lifetime
-
2002
- 2002-02-05 US US10/072,036 patent/US8058008B2/en not_active Expired - Fee Related
-
2007
- 2007-10-29 US US11/927,246 patent/US20090023598A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69804446T3 (de) | Verfahren um quantitativen informationen über einflüsse auf zelluläre reaktionen zu entnehmen | |
| DE60023905T2 (de) | Optische Systemanalyse von Zellen | |
| DE69824174T2 (de) | Ein system zur zellbasierten reihenuntersuchung | |
| Bozza et al. | In vivo imaging of neuronal activity by targeted expression of a genetically encoded probe in the mouse | |
| DE69905049T2 (de) | Auf zellen basiertes screening-system | |
| Ouyang et al. | Visualization of the distribution of autophosphorylated calcium/calmodulin-dependent protein kinase II after tetanic stimulation in the CA1 area of the hippocampus | |
| Bozza et al. | Odorant response properties of convergent olfactory receptor neurons | |
| DE60002562T2 (de) | Ein system für zellbasierte reihenuntersuchungen | |
| DE69903337T2 (de) | Ein screeningsystem auf zellbasis | |
| DE602004013361T2 (de) | Mittel und verfahren zur in-vitro-bestimmung von camp | |
| US7282347B2 (en) | Method for extracting quantitative information relating to interactions between cellular components | |
| EP1121593A2 (en) | Method for extracting quantitative information relating to an influence on a cellular response | |
| Sugai et al. | Novel subdivisions of the rat accessory olfactory bulb revealed by the combined method with lectin histochemistry, electrophysiological and optical recordings | |
| DE60225168T2 (de) | Verfahren zur auswahl bioaktiver wirkstoffe durch lumineszenzkopplung und lebendes zellensystem dafür | |
| KR102234421B1 (ko) | eGRASP를 이용한 세포 사이의 인접 표지 기술 | |
| Seidenthal et al. | Flower/FLWR-1 regulates neuronal activity via the plasma membrane Ca2+ ATPase to promote recycling of synaptic vesicles | |
| DE602004013320T2 (de) | Verfahren zur demonstration eines molekularen ereignisses in einer zelle mittels fluoreszenzmarkerproteinen | |
| Fletcher et al. | Ganglion cell assessment in rodents with retinal degeneration | |
| Leiss | Dendritic spines and structural plasticity in Drosophila | |
| Wang et al. | RETRACTED | |
| DE102006000942A1 (de) | Adenylat-Zyklase, für die Adenylat-Zyklase kodierende Gensequenz, Vektoren und Zellen sowie deren Verwendung | |
| CA2450698A1 (en) | A method for screening substances for effect on camp levels based on intracellular translocation of pka |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8363 | Opposition against the patent | ||
| 8366 | Restricted maintained after opposition proceedings | ||
| 8327 | Change in the person/name/address of the patent owner |
Owner name: FISHER BIOLMAGE APS, SOEBORG, DK |
|
| 8339 | Ceased/non-payment of the annual fee |